NATCO Pharma Limited
NSE: NATCOPHARM BSE: NATCOPHARM
NSE
862.20
13.95 (1.64%)
Prev Close
848.25
Open Price
856.85
Volume
287,000
Today Low / High
850.25 / 864.8
52 WK Low / High
726.8 / 1594
Range
819 - 905
BSE
862.30
13.90 (1.64%)
Prev Close
848.4
Open Price
858.25
Volume
44,350
Today Low / High
850.3 / 863.8
52 WK Low / High
660.05 / 1595
Range
819 - 905
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 862.2 (target range: 819 - 905), reflecting a change of 13.95 (1.64456%). On the BSE, it is listed at 862.3 (target range: 819 - 905), showing a change of 13.9 (1.63838%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
12 Sep
856.85
0.62%
11 Sep
848.00
0.03%
10 Sep
848.10
-0.45%
09 Sep
849.20
-0.94%
08 Sep
857.40
-1.32%
05 Sep
860.95
-0.95%
04 Sep
884.95
-3.32%
03 Sep
867.75
0.49%
02 Sep
869.00
-0.39%
01 Sep
862.95
0.21%
29 Aug
867.15
-0.59%
28 Aug
853.05
1.65%
26 Aug
874.95
-2.25%
25 Aug
884.05
-1.04%
22 Aug
885.00
-0.29%
21 Aug
892.00
-1.21%
20 Aug
892.70
-0.43%
19 Aug
875.25
1.99%
18 Aug
883.95
-1.07%
NATCO Pharma Limited Graph
NATCO Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for NATCO Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 862.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 862.30 | 870.92 | 783.83 - 958.02 |
| 879.55 | 703.64 - 1,055.46 | ||
| 888.17 | 621.72 - 1,154.62 | ||
| Bearish Scenario | 862.30 | 853.68 | 768.31 - 939.04 |
| 845.05 | 676.04 - 1,014.06 | ||
| 836.43 | 585.50 - 1,087.36 |
Overview of NATCO Pharma Limited
ISIN
INE987B01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
953,369
Market Cap
154,428,642,000
Last Dividend
5
Official Website
IPO Date
1996-01-01
DCF Diff
-1,183.99
DCF
2,067
Financial Ratios Every Investor Needs
Stock Dividend of NATCOPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-19 | August 19, 25 | 2 | 2 | 2025-08-19 | 2025-08-26 | |
| 2025-02-18 | February 18, 25 | 1.5 | 1.5 | 2025-02-18 | 2025-03-14 | |
| 2024-11-27 | November 27, 24 | 1.5 | 1.5 | 2024-11-27 | 2024-12-04 | |
| 2024-08-23 | August 23, 24 | 3 | 3 | 2024-08-23 | 2024-09-11 | |
| 2024-02-26 | February 26, 24 | 1.25 | 1.25 | 2024-02-26 | 2024-03-04 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,429.50 Cr | 689.80 Cr | 2,910.00 Cr | 0.6570 | 0.00 Cr | 0.00 Cr | 1,960.80 Cr | 1,885.40 Cr | 105.26 | 2,550.50 Cr | 0.4256 |
| 2024-03-31 | 4,002.00 Cr | 862.50 Cr | 3,139.50 Cr | 0.7845 | 121.10 Cr | 115.30 Cr | 2,596.20 Cr | 1,388.30 Cr | 77.34 | 1,879.50 Cr | 0.3469 |
| 2023-03-31 | 2,707.10 Cr | 627.30 Cr | 2,079.80 Cr | 0.7683 | 90.20 Cr | 106.90 Cr | 876.40 Cr | 715.30 Cr | 39.18 | 1,040.20 Cr | 0.2642 |
| 2022-03-31 | 1,904.90 Cr | 681.50 Cr | 1,223.40 Cr | 0.6422 | 176.90 Cr | 81.80 Cr | 219.90 Cr | 170.00 Cr | 9.32 | 362.50 Cr | 0.0892 |
| 2021-03-31 | 2,056.10 Cr | 531.80 Cr | 1,524.30 Cr | 0.7414 | 142.50 Cr | 429.60 Cr | 931.10 Cr | 440.90 Cr | 24.20 | 606.60 Cr | 0.2144 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,176.00 Cr | 8,630.80 Cr | 1,018.50 Cr | 7,607.0000 Cr | 279.40 Cr | -1,896.60 Cr | 765.80 Cr | 2,657.30 Cr | 0.00 Cr | 0.00 Cr | 335.10 Cr | 943.5000 Cr |
| 2024-03-31 | 70.40 Cr | 6,906.30 Cr | 1,053.20 Cr | 5,853.1000 Cr | 386.10 Cr | 315.70 Cr | 791.70 Cr | 2,435.00 Cr | 0.00 Cr | 0.00 Cr | 139.80 Cr | 972.8000 Cr |
| 2023-03-31 | 131.90 Cr | 5,657.40 Cr | -3,480.00 Cr | 4,873.8000 Cr | 166.70 Cr | 34.80 Cr | 742.90 Cr | 2,303.40 Cr | 112.90 Cr | 87.00 Cr | -925.90 Cr | 683.1000 Cr |
| 2022-03-31 | 111.10 Cr | 5,109.10 Cr | 845.50 Cr | 4,263.6000 Cr | 432.00 Cr | 320.90 Cr | 762.00 Cr | 2,308.40 Cr | 87.70 Cr | 1.30 Cr | -565.10 Cr | 710.4000 Cr |
| 2021-03-31 | 25.80 Cr | 4,791.90 Cr | 668.50 Cr | 4,121.6000 Cr | 283.90 Cr | 258.10 Cr | 798.20 Cr | 2,237.20 Cr | 1.30 Cr | 1.10 Cr | -625.00 Cr | 525.6000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,696.8000 Cr | -1,414.5000 Cr | -210.7000 Cr | 1,428.0000 Cr | 49.6000 Cr | 120.0000 Cr | -511.6000 Cr | 1,885.4000 Cr | -89.2000 Cr | -107.8000 Cr | -65.3000 Cr |
| 2024-03-31 | 1,211.6000 Cr | -1,032.7000 Cr | -246.9000 Cr | 852.9000 Cr | -61.5000 Cr | 70.4000 Cr | -339.4000 Cr | 1,388.3000 Cr | 197.8000 Cr | -170.8000 Cr | 42.4000 Cr |
| 2023-03-31 | 849.1000 Cr | -477.1000 Cr | -363.0000 Cr | 643.5000 Cr | 20.8000 Cr | 131.9000 Cr | -205.6000 Cr | 861.9000 Cr | -239.0000 Cr | -100.4000 Cr | 19.1000 Cr |
| 2022-03-31 | 46.5000 Cr | -5.3000 Cr | 34.8000 Cr | -196.2000 Cr | 85.3000 Cr | 111.1000 Cr | -242.7000 Cr | 202.2000 Cr | -2.4000 Cr | -82.2000 Cr | 56.4000 Cr |
| 2021-03-31 | 298.8000 Cr | -103.3000 Cr | -185.7000 Cr | 44.2000 Cr | 6.0000 Cr | 25.8000 Cr | -254.6000 Cr | 579.6000 Cr | -48.4000 Cr | -113.9000 Cr | -240.2000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,328.90 Cr | 233.00 Cr | 1,095.90 Cr | 0.8247 | 513.40 Cr | 480.70 Cr | 26.84 | 632.70 Cr | 0.3617 |
| 2025-03-31 | 1,221.00 Cr | 506.90 Cr | 714.10 Cr | 0.5848 | 449.80 Cr | 406.60 Cr | 22.70 | 614.40 Cr | 0.3330 |
| 2024-12-31 | 474.80 Cr | 82.80 Cr | 392.00 Cr | 0.8256 | -8.20 Cr | 133.00 Cr | 7.43 | 215.10 Cr | 0.2801 |
| 2024-09-30 | 1,371.10 Cr | 177.60 Cr | 1,193.50 Cr | 0.8705 | 758.50 Cr | 677.30 Cr | 37.81 | 868.10 Cr | 0.4940 |
| 2024-06-30 | 1,362.60 Cr | 366.30 Cr | 996.30 Cr | 0.7312 | 760.70 Cr | 668.50 Cr | 37.32 | 852.90 Cr | 0.4906 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,176.00 Cr | 320.80 Cr | 2,496.80 Cr | 1,256.00 Cr | 765.80 Cr | 5,270.00 Cr | 2,657.30 Cr | 8,630.80 Cr | 1,018.50 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,463.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7,156.80 Cr |
| 2024-09-30 | 104.60 Cr | 2,358.80 Cr | 2,463.40 Cr | 1,445.80 Cr | 774.60 Cr | 5,001.50 Cr | 2,538.20 Cr | 8,244.70 Cr | 1,087.90 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1,849.20 Cr | 0.00 Cr | 0.00 Cr | 1,849.20 Cr | 0.00 Cr | 0.00 Cr | -5,853.10 Cr |
| 2024-03-31 | 952.90 Cr | 443.50 Cr | 1,396.40 Cr | 1,268.50 Cr | 700.50 Cr | 4,023.50 Cr | 2,435.00 Cr | 6,906.30 Cr | 1,053.20 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 133.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 677.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 668.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 386.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 212.70 Cr | 88.40 Cr | 0.00 Cr | 0.00 Cr | 88.40 Cr | 807.90 Cr | 719.50 Cr | 0.00 Cr | 88.40 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-11-26 | November 26, 15 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,616.60 | ₹3,878,676,048,000.00 | ₹1,878,887.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,026.50 | ₹1,599,848,928,500.00 | ₹487,570.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,566.20 | ₹1,206,962,559,000.00 | ₹139,352.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,316.70 | ₹1,095,964,560,653.00 | ₹1,042,670.00 |
| Mankind Pharma Limited | MANKIND | ₹2,579.60 | ₹1,064,750,578,074.00 | ₹181,489.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,044.75 | ₹1,051,258,792,500.00 | ₹559,507.00 |
| Lupin Limited | LUPIN | ₹2,043.40 | ₹933,333,167,000.00 | ₹1,611,273.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,448.00 | ₹651,390,120,000.00 | ₹120,660.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,094.40 | ₹635,629,708,800.00 | ₹793,814.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,132.50 | ₹601,793,632,500.00 | ₹615,366.00 |
| Laurus Labs Limited | LAURUSLABS | ₹896.05 | ₹483,710,191,250.00 | ₹1,298,692.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹980.40 | ₹375,068,694,643.00 | ₹176,773.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,314.80 | ₹333,570,019,200.00 | ₹237,352.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,579.10 | ₹322,222,437,600.00 | ₹58,260.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,699.90 | ₹266,197,540,400.00 | ₹56,240.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,518.00 | ₹246,651,927,918.00 | ₹287,476.00 |
| Piramal Enterprises Limited | PEL | ₹1,083.70 | ₹245,650,948,600.00 | ₹565,474.00 |
| Eris Lifesciences Limited | ERIS | ₹1,675.90 | ₹228,269,311,300.00 | ₹711,885.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,003.50 | ₹225,087,500,000.00 | ₹7,058.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,049.00 | ₹205,907,065,100.00 | ₹157,007.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹946.50 | ₹186,046,879,500.00 | ₹132,074.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,122.30 | ₹178,761,066,300.00 | ₹82,149.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,245.60 | ₹170,691,873,520.00 | ₹78,387.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹862.20 | ₹154,428,642,000.00 | ₹287,000.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹534.35 | ₹129,656,821,400.00 | ₹1,274,862.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,243.50 | ₹103,638,353,900.00 | ₹6,067.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹926.35 | ₹83,957,850,833.00 | ₹170,096.00 |
| Strides Pharma Science Limited | STAR | ₹909.75 | ₹83,854,113,825.00 | ₹182,119.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹827.60 | ₹80,931,748,840.00 | ₹90,322.00 |
| FDC Limited | FDC | ₹463.35 | ₹75,438,013,500.00 | ₹27,055.00 |
| Innova Captab Limited | INNOVACAP | ₹859.60 | ₹49,190,549,828.00 | ₹33,571.00 |
| Suven Life Sciences Limited | SUVEN | ₹224.63 | ₹48,978,481,767.00 | ₹179,307.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹509.65 | ₹46,515,755,500.00 | ₹129,437.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.10 | ₹46,439,098,200.00 | ₹131,426.00 |
| Sequent Scientific Limited | SEQUENT | ₹182.51 | ₹45,688,640,850.00 | ₹212,635.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,380.30 | ₹39,367,781,700.00 | ₹11,398.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹369.25 | ₹37,027,651,500.00 | ₹37,782.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹710.75 | ₹36,048,600,325.00 | ₹42,599.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹506.40 | ₹35,653,497,120.00 | ₹17,743.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹115.76 | ₹33,978,685,520.00 | ₹10,738,156.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹677.55 | ₹32,626,065,150.00 | ₹56,274.00 |
| Hikal Limited | HIKAL | ₹257.45 | ₹31,743,842,450.00 | ₹240,530.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.90 | ₹29,534,720,600.00 | ₹3,571,211.00 |
| Indoco Remedies Limited | INDOCO | ₹299.05 | ₹27,586,734,495.00 | ₹342,407.00 |
| Alembic Limited | ALEMBICLTD | ₹103.16 | ₹26,489,631,017.00 | ₹256,891.00 |
Key Executives
President of Technical Affairs & Whole Time Director
Dr. Donthineni Linga Rao M.D.
Gender: Not Specified
Year Born: 1952
Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management
N. Sadasiva Rao
Gender: Not Specified
Year Born:
Senior Vice President of HR & Organisational Development
Mr. A. Lakshminarayana
Gender: male
Year Born: 1963
Company Secretary & Compliance Officer
Mr. Chekuri Venkat Ramesh C.S.
Gender: male
Year Born:
Executive Vice President of Corporate Engineering Services & Whole Time Director
Mr. Potluri Sivaramakrishna Prasad
Gender: male
Year Born: 1958
Vice President of Marketing & Sales - Domestic
James Rajakumar
Gender: Not Specified
Year Born:
MD & Chairman
Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS.
Gender: male
Year Born: 1945
Chief Executive Officer & Vice Chairman
Mr. Rajeev Nannapaneni
Gender: male
Year Born: 1977
Vice President & Head of Operations
Nadella Malleswara Rao
Gender: Not Specified
Year Born:
Chief Financial Officer
Mr. S. V. V. N. Appa Rao
Gender: male
Year Born:
FAQs about NATCO Pharma Limited
Who is the CEO of the company?
The CEO is Rajeev Nannapaneni.
What is the current market price of the stock?
The current price is ₹862.20.
What is the 52-week price range?
The range is ₹726.8-1616.
What is the market capitalization of the company?
The market capitalization is ₹15,442.86 crores.
What is the dividend yield?
The dividend yield is 0.58%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 9.10.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of NATCO Pharma Limited (ISIN: INE987B01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹15,442.86 crores and an average daily volume of 953,369 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.